Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks ADC effectiveness in advanced breast cancer

NCT ID NCT06774027

Recruiting now Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatment. The goal is to gather real-world data to guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Antibody-drug conjugates (ADCs)
What this could lead to
If successful, this study could provide real-world evidence on how well sequential ADC treatments work for HER2-negative metastatic breast cancer, helping doctors make better treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE BREAST CANCER HER2-NEGATIVE BREAST CARCINOMA HR+/HER2- BREAST CANCER METASTATIC BREAST CANCER METASTATIC TRIPLE NEGATIVE BREAST CANCERS METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.